Oral delafloxacin: Phase III started

Melinta began the open-label, U.S. Phase III PROCEEDING trial to compare once-daily 900 mg oral delafloxacin vs. intramuscular ceftriaxone in about 757 patients with uncomplicated cervical, urethral, ...